Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Anthi Bouhla, MD, Frieda Kontsioti, PhD, Zoi Tsakiraki, MD, Sotirios Papageorgiou, MD PhD, Efthimia Mpazani, MD, Irene Glezou, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Athanasios Galanopoulos, MD PhD, Argiris Symeonidis, MD PhD, Nora-Athina Viniou, MD PhD, Kalliopi Zafeiropoulou, Ioannis Kotsianidis, MD PhD, Periklis Foukas, MD PhD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5403.

https://doi.org/10.1182/blood-2019-122424

Published: 2019

Journal Articles

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Elena E. Solomou, MD, Alexandra Kourakli, MD PhD, Anna Vardi, MD PhD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, MD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Aikaterini Palla, Athina Vyniou, Charalampos Pontikoglou, MD PhD, Panagiotis T Diamantopoulos, MD PhD, Theodoros Vassilakopoulos, MD, Aikaterini Megalakaki, Eleni Variami, Helen A. Papadaki, MD PhD, George Vassilopoulos, MD PhD, Achilles Anagnostopoulos, Argiris Symeonidis, MD PhD

Blood (2019) 134 (Supplement_1): 5417.

https://doi.org/10.1182/blood-2019-131003

Published: 2019

Journal Articles

Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death

Blood (2018) 132 (Supplement 1): 4385.

https://doi.org/10.1182/blood-2018-99-115928

Published: 2018

Journal Articles

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Ioannis Tsonis, MD, Nikolaos Kanellias, MD, Vasileios Lazaris, Panayiotis Panayiotidis, MD PhD, Damianos Sotiropoulos, MD, Theodoros Vassilakopoulos, MD, Zoi Arapidou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Dimitrios Boutsis, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Theoni Leonidopoulou, MD, Gerasimos Pangalis, MD, Maria Papaioannou, Sophia Polychronopoulou, MD PhD, Charalampos Pontikoglou, MD PhD, Elias Poulakidas, Christos Poziopoulos, MD, Panagiotis Repousis, MD, Maria Topalidou, Kalliopi Vallianatou, Elina Vervessou, MD, Nora-Athina Viniou, Maria Angelopoulou, MD, Ioannis Baltadakis, MD, Maria Dimou, MD PhD, Eleni Gavriilaki, MD, Theodoros Iliakis, MD, Argiris Symeonidis, MD PhD, Sossana Delibasi, MD, Maria Papathanassiou, Theodoros Marinakis, Panagiotis Tsirigotis, MD, Nikolaos Charchalakis, PhD, Evangelos Terpos, MD PhD, Maria Pagoni

Blood (2018) 132 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2018-99-116693

Published: 2018

Journal Articles

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Blood (2018) 132 (Supplement 1): 3107.

https://doi.org/10.1182/blood-2018-99-115206

Published: 2018

Journal Articles

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Ioannis Kotsianidis, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, Alexandra Kourakli, Theodoros Vassilakopoulos, MDPhD, Menelaos Konstantinos Papoutselis, Zoi Topouzoglou, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitrios Τsokanas, Argiris Symeonidis, MD PhD

Blood (2017) 130 (Supplement 1): 4251.

https://doi.org/10.1182/blood.V130.Suppl_1.4251.4251

Published: 2017

Journal Articles

Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group

Athanasios G. Galanopoulos, MD PhD, Christos K. Kontos, PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, MD PhD, Alexandra Kourakli, MD, Vassiliki Pappa, MD, Thomas Tsiambalis, Anastasia Pouli, MDPhD, Panayiotis Panayiotidis, MD PhD, Paraskevi Roussou, Stamatis Karakatsanis, Kalliopi Zafeiropoulou, Maria Dimou, Theodoros P. Vassilakopoulos, MD PhD, Anna Vardi, MD PhD, Dimitrios Tsokanas, George Drakos, Eleftheria Hatzimichael, Aikaterini Megalakaki, Panagiotis Repousis, MD, Maria Kotsopoulou, Elena E. Solomou, MD PhD, Georgia Kaiafa, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, PhD, Eleni Bouronikou, George Vassilopoulos, MD PhD, Vasileios Lazaris, Athanasios Galanopoulos, MD PhD, Panagiotis Theodorou Diamantopoulos, MD PhD, Flora Kontopidou, Zoi Topouzoglou, Stamatina Kalyva, Helen A. Papadaki, MD PhD, Apostolos Hatzitolios, Achilles Anagnostopoulos, Nikolaos Anagnostopoulos, Nora-Athina Viniou

Blood (2017) 130 (Supplement 1): 2979.

https://doi.org/10.1182/blood.V130.Suppl_1.2979.2979

Published: 2017

Journal Articles

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

Argiris Symeonidis, MD PhD, Alexandra Kourakli, MD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, Eleftheria Hatzimichael, Theodoros Vassilakopoulos, MDPhD, Aikaterini Palla, Vassiliki Pappa, MD, Evgenia Verigou, Zafeirios Kartasis, MD, Eirini Katodritou, Maria Pagoni, Theodora Assimakopoulou, Charalampos Pontikoglou, MD PhD, Maria Dimou, George Xanthopoulidis, Maria K. Angelopoulou, MD, Maria Kotsopoulou, Dimitra Liapi, Despina Mparmparousi, Evridiki Michali, Anna Kioumi, Nora-Athina Viniou, Achilles Anagnostopoulos, Vassiliki Labropoulou, Maria Dalekou, Michael Voulgarelis, MD PhD, Efthymia Vlachaki, Anna Christoforidou, Ioannis Adamopoulos, MD, Akrivi Kostourou, Petros Laos, Evangelos Terpos, MD PhD, Eleni Kapsali, George Vassilopoulos, MD PhD, Helen A. Papadaki, MD PhD, Panayiotis Panayiotidis, MD PhD, Athanasios Galanopoulos, MD PhD

Blood (2017) 130 (Supplement 1): 1696.

https://doi.org/10.1182/blood.V130.Suppl_1.1696.1696

Published: 2017

Journal Articles

The Clinical Significance of Chromosome 17 Abnormalities in Myelodysplastic Syndrome Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Blood (2017) 130 (Supplement 1): 1701.

https://doi.org/10.1182/blood.V130.Suppl_1.1701.1701

Published: 2017

Journal Articles

Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group

Athanasios Galanopoulos, MD PhD, Christos K. Kontos, Nora-Athina Viniou, MD PhD, Ioannis Kotsianidis, MD PhD, Vassiliki Pappa, MD PhD, Aleka Kourakli, MD PhD, Anastasia Pouli, Panayiotis Panayiotidis, MD PhD, Paraskevi Roussou, MD PhD, Kalliopi Zafeiropoulou, Stamatis Karakatsanis, Maria Dimou, Anna Vardi, Theodoros Vassilakopoulos, MD PhD, Dimitris Tsokanas, Eleftheria Hatzimichael, MD PhD, Aikaterini Megalakaki, MD, Georgia D Kaiafa, MD PhD, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, MD PhD, Eleni Bouronikou, MD PhD, George Vassilopoulos, MD PhD, Vasilios Lazaris, Maria Spiliotopoulou, Panagiotis Theodorou Diamantopoulos, Flora Kontopidou, MD PhD, Zoi Topouzoglou, Stamatina Kalyva, Helen A. Papadaki, MD PhD, Apostolos I Hatzitolios, Professor of Internal MDcine, Achilles Anagnostopoulos, MD, Evangelos Briasoulis, MD PhD, Nikolaos I. Anagnostopoulos, MD, Argiris S. Symeonidis, MD PhD

Blood (2016) 128 (22): 2004.

https://doi.org/10.1182/blood.V128.22.2004.2004

Published: 2016

Journal Articles

Safety and Efficacy of Azacitidine in Myelodysplastic Syndrome (MDS) Patients with Mild and Moderate Renal Impairment

Evdoxia Douvali, Menelaos Papoutselis, Emmanuil Spanoudakis, Eleytherios Moustakides, Emilia Tsakiroglou, Konstantinos Tsatalas, Ioannis Kotsianidis, MD, PhD

Blood (2012) 120 (21): 1716.

https://doi.org/10.1182/blood.V120.21.1716.1716

Published: 2012

Journal Articles

The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine

Paraskevi Miltiades, Eleytheria Labrianidou, Theodoros P. Vassilakopoulos, Sotirios G Papageorgiou, Athanasios G. Galanopoulos, Sofia Vakalopoulou, MD, Ass.Prof.Hematology, Vassilia Garypidou, Evangelia Nakou, Emmanuil Spanoudakis, Maria Papaioannou, Helen A. Papadaki, MD, PhD, Vasiliki Pappa, Konstantinos Tsatalas, Ioannis Kotsianidis, MD, PhD

Blood (2012) 120 (21): 3795.

https://doi.org/10.1182/blood.V120.21.3795.3795

Published: 2012

Journal Articles

The Diagnostic Value of CD1d Expression In Leukemic B-Chronic Lymphoproliferative Disorders (B-CLPDs)

Eleytherios Moustakidis, Emmanuil Spanoudakis, Irene Bouchliou, Evangelia Nakou, Paraskevi Miltiades, asiliki Kotoula, V, Dimitrios Margaritis, George Bourikas, Richard Szydlo, Anastasios Karadimitris, Konstantinos Tsatalas, MD, PhD, Ioannis Kotsianidis, MD, PhD

Blood (2010) 116 (21): 3576.

https://doi.org/10.1182/blood.V116.21.3576.3576

Published: 2010

NARROW

Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

The Clinical Significance of Chromosome 17 Abnormalities in Myelodysplastic Syndrome Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group

Safety and Efficacy of Azacitidine in Myelodysplastic Syndrome (MDS) Patients with Mild and Moderate Renal Impairment

The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine

The Diagnostic Value of CD1d Expression In Leukemic B-Chronic Lymphoproliferative Disorders (B-CLPDs)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only